State of New Jersey Common Pension Fund D Invests $951,000 in Supernus Pharmaceuticals, Inc. $SUPN

Posted by Francis Steltz on May 12th, 2026

State of New Jersey Common Pension Fund D purchased a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) during the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 19,139 shares of the specialty pharmaceutical company’s stock, valued at approximately $951,000.

A number of other hedge funds have also bought and sold shares of SUPN. Royal Bank of Canada grew its position in shares of Supernus Pharmaceuticals by 68.1% during the 1st quarter. Royal Bank of Canada now owns 11,669 shares of the specialty pharmaceutical company’s stock worth $382,000 after purchasing an additional 4,729 shares in the last quarter. AQR Capital Management LLC raised its position in shares of Supernus Pharmaceuticals by 35.2% in the first quarter. AQR Capital Management LLC now owns 85,224 shares of the specialty pharmaceutical company’s stock valued at $2,791,000 after buying an additional 22,182 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Supernus Pharmaceuticals by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,860 shares of the specialty pharmaceutical company’s stock valued at $978,000 after buying an additional 1,297 shares during the period. Millennium Management LLC boosted its stake in shares of Supernus Pharmaceuticals by 370.5% in the first quarter. Millennium Management LLC now owns 143,356 shares of the specialty pharmaceutical company’s stock valued at $4,695,000 after buying an additional 112,886 shares during the period. Finally, Empowered Funds LLC grew its position in Supernus Pharmaceuticals by 16.0% during the first quarter. Empowered Funds LLC now owns 48,045 shares of the specialty pharmaceutical company’s stock worth $1,573,000 after buying an additional 6,619 shares in the last quarter.

Wall Street Analyst Weigh In

Several brokerages have weighed in on SUPN. Zacks Research raised Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Friday, March 27th. Wall Street Zen raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, Craig Hallum set a $65.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $62.17.

Get Our Latest Stock Analysis on Supernus Pharmaceuticals

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ:SUPN opened at $49.37 on Tuesday. Supernus Pharmaceuticals, Inc. has a 1 year low of $30.83 and a 1 year high of $59.68. The stock has a market capitalization of $2.87 billion, a price-to-earnings ratio of -96.80, a price-to-earnings-growth ratio of 1.11 and a beta of 0.57. The company’s 50 day simple moving average is $50.88 and its 200 day simple moving average is $49.92.

Insider Transactions at Supernus Pharmaceuticals

In other news, Director Frederick M. Hudson sold 5,369 shares of Supernus Pharmaceuticals stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $50.61, for a total value of $271,725.09. Following the transaction, the director owned 60,413 shares in the company, valued at approximately $3,057,501.93. This trade represents a 8.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Padmanabh P. Bhatt sold 7,250 shares of the company’s stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $49.60, for a total value of $359,600.00. Following the sale, the vice president owned 17,044 shares of the company’s stock, valued at approximately $845,382.40. This represents a 29.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 120,881 shares of company stock worth $6,139,356. 8.80% of the stock is owned by insiders.

About Supernus Pharmaceuticals

(Free Report)

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.